Legend Biotech (STU:9LB) Ending Cash Position: €584 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9LB Legend Biotech Corp STU:9LB
69 GF Score
Price €17.10
GF Value €68.47
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Legend Biotech Ending Cash Position?

Legend Biotech STU:9LB -2.84% 69 Ending Cash Position is €584 Mil as of Jun. 2026. GuruFocus rates STU:9LB with a GF Score™ of 69/100 and a GF Value™ of €68.47 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Legend Biotech's Ending Cash Position for the quarter that ended in Jun. 2026 was €584 Mil.

Legend Biotech's quarterly Ending Cash Position declined from Dec. 2025 (€770 Mil) to Mar. 2026 (€559 Mil) but then increased from Mar. 2026 (€559 Mil) to Jun. 2026 (€584 Mil).

Legend Biotech's annual Ending Cash Position declined from Dec. 2023 (€1,172 Mil) to Dec. 2024 (€274 Mil) but then increased from Dec. 2024 (€274 Mil) to Dec. 2025 (€770 Mil).

Legend Biotech Ending Cash Position Related Terms

Legend Biotech Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Legend Biotech's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Legend Biotech Ending Cash Position Chart

Legend Biotech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 609.71 742.01 1,171.65 273.80 770.22

Legend Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 231.06 237.62 770.22 559.14 584.08
STU:9LB
69GF Score
Legend Biotech Corp STU:9LB
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Legend Biotech Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Legend Biotech's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=244.843+525.38
=770

Legend Biotech's Ending Cash Position for the quarter that ended in Jun. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=561.074+23.003
=584

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of €584 Mil mean?
Legend Biotech (STU:9LB) has a Ending Cash Position of €584 Mil as of Jun. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Legend Biotech and its competitors.
Is Legend Biotech's Ending Cash Position too high?
Legend Biotech's current Ending Cash Position is €584 Mil. Overall, Legend Biotech has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's Ending Cash Position compare to TNGX and ACAD?
Legend Biotech's Ending Cash Position of €584 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Legend Biotech and its competitors. Legend Biotech's current Ending Cash Position is €584 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (STU:9LB) is currently considered Significantly Undervalued. The stock's GF Value™ is €68.47, compared to a current price of €17.10 — trading 75% below its estimated fair value. The current Ending Cash Position is €584 Mil. Legend Biotech's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Legend Biotech (STU:9LB), the current Ending Cash Position is €584 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Legend Biotech (STU:9LB) Overvalued in 2026?

Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued. The current stock price of €17.10 is trading 75% below its estimated GF Value™ of €68.47. GuruFocus considers Legend Biotech to be Significantly Undervalued.

Key valuation signals for STU:9LB:

  • Ending Cash Position: €584 Mil
  • GF Value™: €68.47 vs. price of €17.10 (75% below fair value)
  • GF Score™: 69/100 with 2 warning signs

No single metric tells the full story. See the STU:9LB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Legend Biotech Business Description

Other Exchanges LEGN:USA
Address 2101 Cottontail Lane, Somerset, NJ, USA, 08873
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
69GF Score

Get the complete analysis for STU:9LB

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.10
Price
€68.47
GF Value